Alphabet-backed start-up Isomorphic Labs has added another name to the roster of pharma companies tapping into its AI-based drug discovery engine. Johnson & Johnson's Janssen Biotech unit is the ...

Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday.

Add Yahoo as a preferred source to see more of our stories on Google. Demis Hassabis speaks during the 56th annual World Economic Forum (WEF) meeting in Davos, Switzerland, January 20, 2026.

The AHRQ systematic review included 48 RCTs and two retrospective cohort studies. Lung cancer and mesothelioma were the most commonly addressed types of cancer. Nonpharmacologic interventions such as ...

Read more: A сentury of сhemical warfare: why the global ban matters Swiss becomes first woman to head chemical weapons body Read more: Swiss becomes first woman to head chemical weapons body Bad ...

Isomorphic Labs has raised $600m in its first external funding round as it pushes forward with artificial intelligence (AI)-driven drug discovery. Thrive Capital led the financing round, with ...

In 2024, Demis Hassabis won a Nobel Prize in chemistry for his work in predicting protein structures through his company, Isomorphic Labs. The lab, which broke off from Google's DeepMind in 2021, ...

Ready for a master's that makes a difference? Miami University's Advanced Inquiry Program (AIP) is an innovative online degree, integrating flexible courses with unparalleled experiential learning at ...